Paul M. Barr, M.D. | UR Medicine

Dr. Paul M. Barr

Claim this profile

University of Rochester

Expert in Lung Cancer
Studies Breast Cancer
85 reported clinical trials
166 drugs studied

About Paul M. Barr

Education:

  • Earned an MD from Northeast Ohio Medical University in 2000.

Experience:

  • Completed internship, residency, and chief residency at Case Western Reserve University.
  • Fellowship in Hematology and Oncology at Case Western.
  • Holds subspecialty certification in Hematology and Oncology.
  • Serves as an Associate Professor of Medicine at the University of Rochester.
  • Director of the Clinical Trials Office for the Wilmot Cancer Institute.

Area of expertise

1

Lung Cancer

Global Leader

Paul M. Barr has run 12 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
Stage II
2

Breast Cancer

Paul M. Barr has run 10 trials for Breast Cancer. Some of their research focus areas include:

Stage IV
HER2 positive
Stage II

Affiliated Hospitals

Image of trial facility.

University Of Rochester

Image of trial facility.

Wilmot Cancer Institute At Webster

Clinical Trials Paul M. Barr is currently running

Image of trial facility.

Chemotherapy + Immunotherapy

for Esophageal and Gastric Cancer

This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.

Recruiting

2 awards

Phase 3

2 criteria

Image of trial facility.

Multiple Targeted Therapies

for Meningioma

This trial studies four drugs to treat patients with worsening meningioma. These drugs work by blocking enzymes that the tumor cells need to grow. The trial focuses on patients whose tumors have specific genetic mutations.

Recruiting

1 award

Phase 2

10 criteria

More about Paul M. Barr

Clinical Trial Related

7 years of experience running clinical trials · Led 85 trials as a Principal Investigator · 34 Active Clinical Trials

Treatments Paul M. Barr has experience with

  • Nivolumab
  • Cisplatin
  • Pembrolizumab
  • Carboplatin
  • Cytarabine
  • Cyclophosphamide

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Paul M. Barr specialize in?

Is Paul M. Barr currently recruiting for clinical trials?

Are there any treatments that Paul M. Barr has studied deeply?

What is the best way to schedule an appointment with Paul M. Barr?

What is the office address of Paul M. Barr?

Is there any support for travel costs?